Bulk Raw Materials pantoprazole Powder

CAS:102625-70-7

MF:C16H15F2N3O4S

MW:383.37 

EINECS:600-331-6

Specification: 99% min pantoprazole Powder

Sample: pantoprazole Powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

pantoprazole Powder Usage and Synthesis.

Pantoprazole is a gastric acid inhibiting and anti-ulcer digestive drug, also known as Pantoloc, Pentoprazole, Temenic, Norsen, Fusidan, Pemelu, Pamlisu, and Forcolan, is a new type of proton pump inhibitors (PPIs), belongs to benzimidazole derivatives, is a weak base, is highly ionised in acidic environment, and concentrated in the microtubular lumen of the cells of the gastric lining, and transformed into a highly reactive cyclic sulfinamide cation, covalently binding to the cysteine group of the proton pump on the surface of the microtubule, causing significant irreversible inhibition of the proton pump secretion. It is highly ionised in acidic environment and concentrated in the lumen of microtubules of gastric wall cells, converted into highly active cyclic sulfinamide cation, which covalently binds with the cysteine group of proton pump on the surface of microtubule lumen, and irreversibly deactivates the proton pump, and significantly inhibits the gastric acid secretion.

At the same time, it can relieve the pain symptoms of duodenal ulcer patients, improve the symptoms of nausea, bloating, acid reflux, belching and so on, and promote the repair of ulcers.

Uses and functions of pantoprazole.

It is used in the treatment of active peptic ulcers reflux oesophagitis and Dreux-Alexander's syndrome.

Anti-ulcer drugs. Proton pump inhibitors of the stomach.

Used in combination with other antibacterial drugs (clarithromycin, amoxicillin and metronidazole), it can eradicate Helicobacter pylori infections. Duodenal ulcer, gastric ulcer, moderate to severe reflux oesophagitis.

Mechanism of action: irreversible proton pump inhibitor, reduce gastric acid secretion. In the acidic environment of gastric lining cells, it is activated to cyclic sulfonamide, which then specifically binds to the sulfhydryl group on the proton pump (i.e., HtK+-ATPase) with covalent bonding, so that it loses the function of acid secretion.

Pharmacological Effects of pantoprazole.

Pantoprazole is a benzimidazole derivative that inhibits gastric acid secretion by specifically binding to proton pumps on gastric mural cells and decreasing H+-K+-ATPase activity in the mural cells. Compared with omeprazole, it has a weaker inhibitory effect on cytochrome P450 enzymes.

1, When this product is taken at the same time with drugs whose bioavailability depends on pH (e.g. ketoconazole), the effect of this product on its absorption should be taken into account.

Pantoprazole is metabolised in the liver by the cytochrome P450 enzyme system, therefore any other drug metabolised by this enzyme system cannot be excluded from the possibility of interaction with this product. Such drugs have been tested in clinical use, such as carbamazepine, caffeine, Valium, diclofenac, digoxin, ethanol, glibenclamide, metoprolol, nifedipine, phenylpropylcoumarin, phenytoin, theophylline, warfarin, and oral contraceptives, etc., and no clinically significant interactions between pantoprazole and these drugs have been observed.

3, Pantoprazole did not interact with concomitantly used antacids.

Production method of pantoprazole Powder.

Condensation of 2-mercapto-5-difluoromethoxy-1H-benzimidazole (I) and 2-chloromethyl-3,4-dimethoxypyridine hydrochloride, the product (III was then oxidised with m-chloroperbenzoic acid to give the product.